New Trial Alert: Alliance A022102 Gastroesophageal Cancer

January 12, 2023

Alliance A022102: A randomized phase III trial of mFOLFIRINOX +/- nivolumab vs. FOLFOX +/- nivolumab for first-line treatment of metastatic HER2-negative gastroesophageal adenocarcinoma

Haeseong Park, MD, MPH, of Dana-Farber Cancer Institute, leads Alliance A022102 – a phase III trial that compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to mo

New Trial Alert: Alliance A022101 Limited Metastatic Colorectal Cancer

January 11, 2023

Alliance A022101: A pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer: evaluating radiation, ablation, and surgery (ERASur)

Eric D. Miller, MD, PhD, of Ohio State University Medical Center, leads Alliance A022101 (ERASur) – a phase III trial that compares total ablative therapy and usual systemic therapy to usual

New Trial Alert: Alliance A092104 & A022104

December 15, 2022

Alliance A092104: A randomized phase 2/3 study of olaparib plus temozolomide versus investigator’s choice for the treatment of patients with advanced uterine leiomyosarcoma after progression on prior chemotherapy

Overview: This phase II/III trial compares the effect of the combination of olaparib and temozolomide to the usual treatment (trabectedin and pazopanib) for uterine leiomyosarcoma that has spread t

Older News